Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2 0 -deoxyuridine nucleotides induce exon-skipping in vitro †
Introduction
Antisense oligonucleotide (AO)-based therapy has now been established as one of the most promising approaches for the treatment of various diseases. The use of chemically-modied nucleotides is paramount to improve the pharmacokinetics of AO-based therapeutic molecules. Last year, two AO drug candidates, Exondys 51 for the treatment of duchenne muscular dystrophy (DMD) and nusinersen for the treatment of spinal muscular atrophy (SMA), have been approved by the US Food and Drug Administration (FDA), bringing the total number of FDA approved antisense oligonucleotide drugs to four.
1,2 With the approval of Exondys 51 for the treatment of DMD, AOmediated splice modulation has now emerged and been validated as a viable treatment alternative. DMD is a serious Xlinked muscle wasting genetic disorder. 3, 4 Patients with DMD lack dystrophin protein due to mutations in one or more exons of the dystrophin gene required for muscle contraction and protection. Exondys 51 is a 30-nucleotide long phosphorodiamidate morpholino oligomer (PMO) AO targeting exon-51 in the dystrophin gene transcript. In addition, another AO drug candidate drisapersen composed of 2
nucleotides on a phosphorothioate (PS) backbone entered phase-3 clinical trials, and was later rejected by the FDA based on poor efficacy and toxicity issues. So far, several antisense oligonucleotide chemistries have been explored for their potential to modulate splicing or induce exon-skipping. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, only sugar moiety and phosphate backbone modied-AOs have been investigated for exonskipping applications. We envisioned the scope of nucleobase-modied AOs to induce exon-skipping. Towards this, Nielsen and colleagues reported the synthesis of 5-(phenyltriazol)-2 0 -deoxyuridines that showed improved duplex stability when targeting a complementary RNA. [17] [18] [19] [20] Improved duplex stability upon incorporation of 5-(phenyltriazol)-2 0 -deoxyuridine nucleotides is believed to be due to the p-p stacking of the aromatic substituents. Herein, we describe for the rst time that the design and synthesis of 5-(phenyltriazol)- 
Experimental
Design and synthesis of antisense oligonucleotides used in this study
All AOs (Table 1) were prepared in-house on an AKTA Oligopilot synthesizer (GE Healthcare Life Sciences) via standard phosphoramidite chemistry in 1 mmol scale. Synthesized oligonucleotides were deprotected and cleaved from the solid support by treatment with NH 4 OH at 55 C overnight. The crude oligonucleotides were then puried, desalted and veried by HPLC and MALDI-ToF MS analysis (see ESI † for detailed procedure and analysed data).
Melting temperature analysis of the antisense oligonucleotides
Three antisense oligonucleotides: control 2 0 -O-MePS, ON1 and ON2 were prepared at 2 mM concentrations in a buffer solution containing 10 mM NaCl, 0.01 mM EDTA adjusted to pH 7.0 by 10 mM sodium phosphate buffer. The AOs were then mixed with the synthetic complementary RNA sequence (2 mM) at equal volume and denatured at 95 C for 10 minutes followed by cooling down to room temperature and loaded onto a quartz cuvette of 1 mm path-length. The melting process was monitored by Shimadzu UV-1800 with the temperature controller over the range of 20-90 C at a ramp rate of 1.0 C min À1 . T m values were then calculated by the rst derivative.
Cell culture and transfection
H-2K b -tsA58 (H2K) mdx mouse myoblast (provided by Prof. Sue
Fletcher and Prof. Steve Wilton's laboratory, Murdoch University, Australia) were cultured as described previously. 21, 22 Briey, when 60-80% conuent, primary mdx myoblast cultures were treated with trypsin (Life Technologies) and seeded at a density of 2 Â 10 4 cells per well into 24 well plates. The plates were pretreated with 50 mg ml À1 poly-D-lysine (Sigma) and 100 mg ml
À1
Matrigel (Corning). Cultures were then allowed to differentiate into myotubes in Dulbecco's Modied Eagle Medium (DMEM) containing 5% horse serum by incubating at 37 C, 5% CO 2 for 24 hours. Antisense oligonucleotides were complexed with Lipofectin (Life Technologies) at the ratio of 2 : 1 (Lipofectin : AO) and used in a nal transfection volume of 500 ml per well in a 24-well plate as per the manufacturer's instructions, except that the solution was not removed aer 3 hours.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
RNA was extracted from transfected cells using Direct-zol™ RNA MiniPrep Plus with TRI Reagent® (Zymo Research) as per the manufacturer's instructions. The dystrophin transcripts were then analysed by nested RT-PCR across exons 20-26 as described previously. 22,23 PCR products were separated on 2% agarose gels in Tris-acetate-EDTA buffer and the images were captured on a Fusion Fx gel documentation system (Vilber Lourmat, Marne-la-Vallee, France). Densitometry analyses was performed by Image J soware. 24 To quantify the actual exonskipping efficiency, the amount of exon-23 skipped RT-PCR product is expressed as a percentage of total dystrophin transcript products.
Cell viability assay
Cells were seeded and transfected with the AOs at 50 and 200 nM as described previously. Aer 24 h, cell viability assay was performed using a colorimetric assay (WST-1, Sigma). Briey, WST-1 solution was added at ratio 1 : 10 (v/v) per well and incubated for 4 h at 37 C, 5% CO 2 . The absorbance was then measured with a microplate reader (FLUOstar Omega, BMG Labtech, Germany) at 450 nm. (Table 1) . To assess the binding affinity of the modied AOs against its RNA target, we initially performed the thermal stability analysis using a synthetic complementary RNA sequence (Table 1) to the unmodied control 2 0 -O-MePS AO sequence, probably due to stronger p-p stacking interaction (Table 1) . Fig. 1 Structural presentation of the nucleic acid analogues used in this study. We then evaluated the exon-skipping efficiency of the AOs in vitro using H-2K b -tsA58 (H2K) mdx mouse myotubes. Briey, H2K mdx myoblasts were plated for differentiation into myotubes 24 h prior to transfection with the AOs using lipid-based delivery agent Lipofectin (2 : 1 ratio of lipo : AO) at 25, 50, 100 and 200 nM. The cells were then collected aer 24 h of treatment and the RNA was extracted followed by reversetranscriptase polymerase chain amplication (RT-PCR) analysis by amplifying the product across exon 20-26 as previously reported. 22, 23 The results clearly demonstrated that all three AOs efficiently induced exon-23 skipping in DMD transcript at all concentrations from 25 nM to 200 nM ( Fig. 2A) in a dosedependent manner by yielding the skipped product of 688 bp from the full-length 901 bp product. The actual exon-skipping efficiencies of the AOs were analysed by densitometry (semiquantitative) and the percentage of exon-23 skipping was determined by analysing the amount of exon-23 RT-PCR product over the full-length dystrophin product band. Densitometry results revealed that the ON1 containing two distantly positioned 5-(phenyltriazol)-2 0 -deoxyuridines achieved slightly higher exon-23 skipping efficiency at 25 nM (57%) and 50 nM (61%) concentrations compared to the control 2 0 -O-MePS AO (51% and 60% respectively at 25 and 50 nM) ( Fig. 2A and B) . However, at higher concentrations, the full 2 0 -O-MePS AO showed higher exon-23 skipping efficacy (69% at 100 and 70% 200 nM; Fig. 2A and B) . Notably, ON2 containing two consecutive 5-(phenyltriazol)-2 0 -deoxyuridines showed slightly reduced exon-skipping efficacy at both lower (47 and 54% at 25 and 50 nM, respectively) and higher concentrations (57 and 62% at 100 and 200 nM, respectively; Fig. 2A and B) . This observation does not correlate with the melting temperature analysis data. We speculate that this may be due to the structural features of the AO in the cellular environment which may distort the AOtarget complex because of the positioning of the 5-(phenyltriazol)-2 0 -deoxyuridine monomers, and this needs to be further investigated.
Results and discussion
We also observed the presence of another weak product band at 542 bp which is believed to be due to the unfavourable dual exon-22/23 skipping ( Fig. 2A) . All three AOs induced the dual exon-22/23 skipping at all concentrations and the intensity increases with increasing concentrations, however, the yields were generally very low in all cases, ranging from 15-28%, compared to the major expected exon-23 skipped product of 688 bp (51-70%). ON1 induced slightly more dual exon-22/23 skipping compared to other AOs at 100 nM (28%), but the percentage reduced to 25% at 200 nM, which is comparable to the control AO (26%) and ON2 (24%) (Fig. 2B) .
We then performed the cell viability assay to assess the toxicity of the base-modied AOs in parallel to 2 0 -O-MePS AO.
Overall, the AOs (2 0 -O-MePS, ON1 and ON2, respectively) were found to be relatively non-toxic to cells at 50 nM dose with 95, 96 and 98% cell viable compared to the untreated (Fig. 3 ). In line with our previous report, 6 the 2 0 -O-MePS AO was found to be slightly toxic at 200 nM with the cell vitality reduced to 84%, while the nucleobase modied ON1 and ON2 maintained 93 and 91% of cell viability respectively at 200 nM (Fig. 3) . These results may indicate the benet of incorporating the nucleobasemodied nucleotides such as 5-(phenyltriazole)-2 0 -deoxyuridine in reducing the cytotoxic effect of the 2 0 -O-MePS AO.
It is worth mentioning that the 5-(phenyltriazole)-2 0 -deoxyuridine building block is a logical choice since it is one of the nucleobase-modications that has demonstrated the most positive effects on the thermal duplex stability to date, 17 but this property requires at least two of these modications are placed consecutively. Not only is this work the rst time this building block is incorporated along with 2 0 -O-Me in phosphorothioated oligonucleotides, but it is also the rst time that this building block is examined in vitro in cells for antisense applications. Notably, the current work unintuitively demonstrates that the exon-skipping potential of the oligonucleotides is slightly better when the 5-(phenyltriazole)-2 0 -deoxyuridine building blocks are placed distantly compared to consecutively, and that the melting temperature (i.e. hybridization strength) is therefore may not be necessarily a good indicator for skipping efficiency in the context of the 5-(phenyltriazol)-2 0 -deoxyuridine building block. As these are only our preliminary investigation towards the application of base-modied AOs in exon-skipping, this nding can help to improvise the AO design in future exonskipping experiments containing base-modied nucleotides with multiple chemistries.
Conclusions
In summary, we have designed and synthesized two 2 0 -O-MePS mixmer RNA AOs containing two 5-(phenyltriazol)-2 0 -deoxyuridine monomers placed at distant positions and consecutively, and evaluated their potential to induce exon-skipping in DMD transcript using H2K mdx mouse myotubes. We found that a 2 0 -O-MePS AO containing two distantly placed 5-(phenyltriazol)-2 0 -deoxyuridines induced higher exon-23 skipping at low concentrations, compared to the previously reported control 2 0 -O-MePS AO. Contrary to the melting temperature analysis data, the AO containing two consecutive 5-(phenyltriazol)-2 0 -deoxyuridines were not as effective, highlighting the impact of the modied monomer positions. Although we report the rst demonstration of exon-skipping using nucleobase-modied AOs, further investigations are necessary to gain more insights about the positioning and also in combination with other sugar-modied nucleotides such as locked nucleic acid (LNA) nucleotides.
25,26
Our results open the scope of exploring novel base-modied nucleic acid analogues in combination with other chemistries for their potential in constructing efficient exon-skipping AOs.
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